AVIR vs. MRVI, ELVN, PAHC, ZYME, ABCL, REPL, COLL, RCKT, EOLS, and PHVS
Should you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include Maravai LifeSciences (MRVI), Enliven Therapeutics (ELVN), Phibro Animal Health (PAHC), Zymeworks (ZYME), AbCellera Biologics (ABCL), Replimune Group (REPL), Collegium Pharmaceutical (COLL), Rocket Pharmaceuticals (RCKT), Evolus (EOLS), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry.
Atea Pharmaceuticals vs.
Maravai LifeSciences (NASDAQ:MRVI) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.
Atea Pharmaceuticals has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -81.13%. Maravai LifeSciences' return on equity of -6.61% beat Atea Pharmaceuticals' return on equity.
Maravai LifeSciences has higher revenue and earnings than Atea Pharmaceuticals. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Maravai LifeSciences has a beta of -0.08, meaning that its stock price is 108% less volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.
Maravai LifeSciences received 44 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 62.63% of users gave Maravai LifeSciences an outperform vote while only 47.37% of users gave Atea Pharmaceuticals an outperform vote.
Maravai LifeSciences presently has a consensus target price of $10.28, indicating a potential upside of 150.15%. Atea Pharmaceuticals has a consensus target price of $6.88, indicating a potential upside of 122.65%. Given Maravai LifeSciences' higher probable upside, analysts clearly believe Maravai LifeSciences is more favorable than Atea Pharmaceuticals.
In the previous week, Maravai LifeSciences had 3 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for Maravai LifeSciences and 1 mentions for Atea Pharmaceuticals. Maravai LifeSciences' average media sentiment score of 0.27 beat Atea Pharmaceuticals' score of 0.00 indicating that Maravai LifeSciences is being referred to more favorably in the media.
50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 0.6% of Maravai LifeSciences shares are owned by insiders. Comparatively, 17.8% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Maravai LifeSciences beats Atea Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Atea Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atea Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AVIR) was last updated on 2/22/2025 by MarketBeat.com Staff
Free AVIR Stock Alerts